| Metric | Value ($ M) | vs Q2 FY25 |
|---|---|---|
| Revenue | 1.40 | 0.7% |
| Total Income | 1.40 | 0.7% |
| Expenditure | 5.88 | 100.7% |
| PBT | — | |
| Net Profit | -4.42 | 185.8% |
| OPM | — | |
| NPM | — | |
| EPS | -0.04 | 300.0% |
Plus Therapeutics Reports Q3 2025 Financial Results
04 May 2026 · 4 May, 8:32 am
Summary
Plus Therapeutics announced its Q3 2025 financial results, with a cash and investments balance of $16.6 million. Grant revenue was $1.4 million, slightly down from $1.5 million in Q3 2024. The total operating loss increased to $4.5 million from $3.8 million year-over-year, and the net loss was $4.4 million, or $0.04 per share, compared to $2.9 million, or $0.37 per share, in the prior year. The company also highlighted positive clinical trial results and expanded commercial readiness for its CNSide platform.
Key Highlights
- 1
Plus Therapeutics reported a cash and investments balance of $16.6 million on September 30, 2025, an increase from $6.9 million on June 30, 2025.
- 2
The company recognized $1.4 million in grant revenue in the third quarter of 2025, compared to $1.5 million in the same quarter of 2024.
- 3
Total operating loss for the third quarter of 2025 was $4.5 million, compared to a loss of $3.8 million in the same quarter of 2024.
- 4
Net loss for the third quarter of 2025 was $4.4 million, or a loss of $0.04 per share, compared to a net loss of $2.9 million, or a loss of $0.37 per share, for the same quarter in the prior year.
- 5
The company presented positive ReSPECT-LM Phase 1 single dose escalation trial results at SNO/ASCO CNS Metastases Conference.
- 6
UnitedHealthcare now covers over 51 million people throughout the U.S. for the CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT).
Management Comments
Marc H. Hedrick
M.D.
Our team continues to execute solidly across the three most important business verticals: diagnostics, therapeutics, and capital structure. In the fourth quarter, we plan to build on growing momentum in these three areas as we expand our commercial team and footprint for CNSide, seek to clarify our clinical development and pivotal plan for REYOBIQ™ with the FDA, and bolster our financial position in the capital markets.
Informational and educational content only. Not investment advice.